FDA says it intends to bring GHK-Cu to its compounding advisory committee before the end of February 2027, and no date has been set [2] [3]. Copper peptide serums are also sold over the counter as cosmetics, which FDA does not approve as drugs.
GHK-Cu is a small copper-binding peptide (glycyl-histidyl-lysine with copper) used in skin care and sold online as an injection; no FDA-approved drug contains it [1] [4].
At a glance
A compounded GHK-Cu cream is lawful with a prescription; an injection is not [1].
Injection vs cream: two different answersHuman skin studies come from a review by authors at a skin care company, with few method details [4].
Skin studies on copper peptide creamsFDA cites immune reaction risk and limited human data for injections [5].
Injectable GHK-Cu: what FDA flagged
- FDA-approved products
- NoneWe found no approved drug with GHK-Cu
GHK-Cu has two legal statuses at once, one for injections and one for everything else. Both status boxes are below, each checked against FDA's lists.
Legal status of GHK-Cu (injectable)
Under FDA reviewInjectable GHK-Cu is waiting for an FDA advisory committee review planned before the end of February 2027, and it cannot be legally compounded until FDA acts [1] [7]. Non-injectable GHK-Cu, such as creams, is in Category 1 [1].
- FDA status
- FDA removed it from Category 2 in April 2026 because the nominators withdrew their nominations [9]. That removal did not make it legal to compound [7]. FDA now lists it as "nominated but withdrawn," which is outside every category [5]. It is not in Category 1 and is not on the 503A bulks list, so a 503A pharmacy may not lawfully compound it today [1]. This applies only to injection. Non-injectable GHK-Cu, such as creams, is in Category 1, so a 503A pharmacy may compound it with a prescription [1]. FDA cites immunogenicity risk and limited human data for injectable GHK-Cu [5].
- Advisory committee
- Not yet reviewed. It is one of five peptides FDA plans to bring to the committee: GHK-Cu, LL-37, dihexa, Melanotan II and PEG-MGF [12]. FDA says it intends to hold that review before the end of February 2027 [1]. No date had been set as of Oct 16, 2026 [3].
- FDA-approved products
- None. We found no FDA-approved drug that contains GHK-Cu (injectable).
- Sports (WADA)
- GHK-Cu is not named on the 2026 list [11]. The list's S0 class covers substances with no approval by any government health authority for human use [11]. Whether that class covers GHK-Cu is a judgment call, so athletes should ask their anti-doping agency before use.
- What happens next
- FDA says it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 [1]. No meeting date had been set as of Oct 16, 2026 [3]. Even a favorable vote would not be binding. FDA would still have to act through rulemaking or another formal step [13].
Checked against FDA sources on . We update this box when FDA acts. Report a change: [email protected].
Legal status of GHK-Cu (topical)
Can be compounded with a prescriptionNon-injectable GHK-Cu is in Category 1, so a 503A pharmacy may compound it with a prescription [1]. Skin care products that list copper peptides are also sold as cosmetics [15].
- FDA status
- FDA's Category 1 list includes "GHK-Cu (except for injectable routes of administration)" [1]. Category 1 means FDA does not intend to act against compounders using it while it decides whether to add it to the bulks list [6]. It was removed from Category 1 on April 22, 2026 after the nominator withdrew, then added back after a May 5, 2026 clarification [1]. Compounding is allowed only for an individual patient with a valid prescription [7]. Injectable GHK-Cu is not in Category 1 and may not be compounded [1].
- Advisory committee
- FDA plans to bring GHK-Cu to its advisory committee before the end of February 2027 [1]. No date had been set as of Oct 24, 2026 [3].
- FDA-approved products
- None. We found no FDA-approved drug that contains GHK-Cu. Skin care serums that list copper peptides are sold as cosmetics, which FDA does not approve as drugs [15].
Checked against FDA sources on . We update this box when FDA acts. Report a change: [email protected].
Injection vs cream: two different answers
FDA's Category 1 list includes "GHK-Cu (except for injectable routes of administration)" [1]. Category 1 means FDA does not intend to act against pharmacies compounding it while it decides whether to add it to the 503A bulks list [6]. Compounding still has to be for an individual patient with a valid prescription [7].
The injectable form is a different story. FDA placed it in Category 2 in 2023 over safety concerns and removed it in April 2026 when the nominators withdrew [8] [9]. It now sits on FDA's nominated but withdrawn list, which allows no compounding [5] [7].
There was a brief scare this spring. FDA removed non-injectable GHK-Cu from Category 1 on April 22, 2026 after a nominator withdrew, then said it would add it back after the nominator clarified on May 5, 2026 that it meant to withdraw only the injectable route [1].
What GHK-Cu is
GHK is a three-amino-acid peptide (glycine, histidine, lysine) that binds copper; with copper attached it is called GHK-Cu [4]. It shows up in three very different products: over-the-counter serums sold as cosmetics, compounded prescription creams, and injectable vials sold online. Only the first two have a legal route today [1].
Skin studies on copper peptide creams
The human evidence most often cited is summarized in a 2015 review by Loren Pickart and colleagues, whose listed affiliation is the research department of Skin Biology, a skin care company [4]. The review describes several small cream studies in women; only the eye cream study is described as placebo-controlled [4]:
- A 12-week facial cream study in 71 women with mild to advanced sun damage, reported to reduce fine lines and increase skin density [4].
- A 12-week eye cream study in 41 women, in which the GHK-Cu cream was reported to beat both placebo and a vitamin K cream [4].
- A one-month thigh cream study in which collagen increased in 70% of women on GHK-Cu, compared with 50% on vitamin C cream and 40% on retinoic acid [4].
The review gives few details on methods, and several of the studies it cites are a conference presentation, a university document or a book chapter rather than full peer-reviewed papers [4]. Treat "before and after" claims with that in mind. None of these studies tested injections, hair regrowth or whole-body anti-aging.
Injectable GHK-Cu: what FDA flagged
For injection, FDA's safety page says "there are limited data in humans to inform safety-related considerations" and cites a risk of immune reactions linked to clumping and impurities [5]. No human study of injected GHK-Cu was cited in the sources we reviewed. A federal indictment in Utah in April 2026 listed GHK-Cu among misbranded drugs a physician allegedly received from China and gave to patients; those are allegations, and he is presumed innocent [10].
GHK-Cu side effects
No large trial reports side effect rates for GHK-Cu creams or injections. With injections, FDA's concern is immune reactions [5]. With any new skin product, stop using it if you get a rash, burning or swelling.
Allergic reactions
Hives, swelling of the face, lips or throat, or trouble breathing after any injection or new skin product need emergency care. Call 911. Tell your doctor about any copper peptide product you use.
Getting GHK-Cu legally
Injections
There is no legal way to buy injectable GHK-Cu today
There is no legal way to buy injectable GHK-Cu in the US today. A 503A pharmacy may not compound it for injection [1]. Products labeled "research use only" are not a legal workaround; FDA has rejected that label in warning letters to online sellers [14]. Non-injectable GHK-Cu is different. It is in Category 1, so a pharmacy may compound a cream with a prescription [1].
Creams and other non-injectable forms
Two lawful routes exist for non-injectable GHK-Cu as of Oct 24, 2026:
- A compounded prescription cream or other non-injectable product, made by a 503A pharmacy for you after a prescriber writes a prescription, because non-injectable GHK-Cu is in Category 1 [1] [7]. Compounded products are not FDA-approved, and FDA does not review them for safety, effectiveness or quality.
- Over-the-counter copper peptide serums sold as cosmetics. FDA does not approve cosmetics as drugs.
Prices for both, with dates and sources, are on our legal peptide price tracker. We do not list injectable offers.
The February 2027 review
FDA plans one advisory committee meeting before the end of February 2027 on five substances: LL-37, GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF [2]. FDA's meeting page says the time and place "will be scheduled in the coming months" [2]. A favorable vote would still be advice only; for the July 2026 peptides, FDA had not acted three months later [3]. Related pages: LL-37, dihexa and Melanotan II.
GHK-Cu and anti-doping rules
No version of GHK-Cu, cream or injection, appears by name on the 2026 WADA list [11]. Injections carry more anti-doping risk than skin creams because S0, the list's class for unapproved substances, can reach products with no government approval for therapeutic use [11]. Tested athletes should clear any product with their agency.
What changed
Injectable GHK-Cu
- : FDA's categories document says it intends to consult the advisory committee before the end of February 2027 [1].
- : Non-injectable GHK-Cu, briefly removed from Category 1 on April 22, was added back after the nominator clarified its withdrawal [1].
- : The removal took effect around this date. FDA now lists it as nominated but withdrawn, which does not allow compounding [5] [7].
- : FDA gave seven days' notice that it would remove 12 peptides, including this one, from Category 2 because the nominators withdrew [9].
- : FDA placed it in Category 2, citing significant safety risks [8].
Non-injectable GHK-Cu
- : FDA's updated categories document lists non-injectable GHK-Cu in Category 1 [1].
- : The nominator clarified its withdrawal, and FDA later added non-injectable GHK-Cu back to Category 1 [1].
- : FDA removed non-injectable GHK-Cu from Category 1 after the nominator withdrew [1].
The other substances on FDA's February 2027 review list with their own pages: LL-37, dihexa and Melanotan II. Already voted on in July 2026: TB-500 and KPV.
How we check
We rechecked FDA's categories document (updated May 14, 2026) and the advisory committee page on Oct 24, 2026 [1] [2]. GHK-Cu also appears in four-peptide blends, covered on our KLOW page; see the full peptide status tracker and editorial standards.
Questions people ask
Is GHK-Cu legal?
Partly. As of Oct 24, 2026, non-injectable GHK-Cu is in FDA's Category 1, so a 503A pharmacy may compound a cream for a patient with a prescription, but injectable GHK-Cu may not be compounded [1].
Is a GHK-Cu injection legal?
What are the benefits of GHK-Cu?
What are GHK-Cu side effects?
No large trial reports rates. For injections, FDA cites limited human data and a risk of immune reactions tied to clumping and impurities [5].
Does GHK-Cu help hair growth?
We found no human trial of GHK-Cu for hair that we could cite. The human studies in the 2015 review tested skin creams for wrinkles and collagen [4].
Do I need a prescription for GHK-Cu?
Medical review: pending. A licensed clinician has not yet reviewed this page.
Sources
15 cited
- Bulk drug substances nominated for use in compounding under section 503A (categories document). FDA, May 14, 2026.
- Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027). FDA, Apr 15, 2026.
- Peptides at a crossroads: what wellness providers need to know. Holland & Knight, Oct 16, 2026.
- GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration (Pickart et al.). BioMed Research International, Jul 7, 2015.
- Certain bulk drug substances for use in compounding that may present significant safety risks. FDA, Apr 22, 2026.
- Bulk drug substances used in compounding under section 503A of the FD&C Act. FDA, May 14, 2026.
- FDA peptides do-not-compound list update (2026). Frier Levitt, Apr 16, 2026.
- 503A categories update for September 2023. FDA (copy hosted by the Alliance for Pharmacy Compounding), Sep 29, 2023.
- FDA announces removal of 12 peptides from Category 2 and schedules PCAC meetings. Orrick, Apr 16, 2026.
- Utah licensed osteopathic physician indicted for allegedly receiving misbranded drugs from China. U.S. Attorney's Office, District of Utah, Apr 2026.
- 2026 Prohibited List. World Anti-Doping Agency (copy hosted by Asia Rugby), Sep 2025.
- FDA's peptide rally: what compounders and industry need to know (post 1 of 2). Hyman, Phelps & McNamara (FDA Law Blog), Apr 21, 2026.
- FDA voted yes on six peptides. Now what? The regulatory road ahead. Buchanan Ingersoll & Rooney, Aug 18, 2026.
- Warning letter: USApeptide.com. FDA, Feb 26, 2025.
- Multi-Peptide + Copper Peptides 1% Serum (example cosmetic listing). DECIEM / The Ordinary, Oct 19, 2026.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.